Eli Lilly's Remarkable Financial Performance

Eli Lilly and Co. announced a significant 45% year-over-year increase in its fourth-quarter revenue for 2024, reaching $13.5 billion and surpassing market expectations. The company's net income saw an impressive 101% annual rise to $4.4 billion, with earnings per share (EPS) climbing 102% to $4.88.

Full-Year 2024 Highlights

For the entire year of 2024, Eli Lilly experienced a 32% growth in revenue, totaling $45 billion. Net income and EPS soared by 102% to $10.5 billion and $5.20, respectively. Looking ahead, the company projects 2025 revenue to be in the range of $58 billion to $61 billion, with an EPS forecast of $22.05 to $23.55.

CEO's Optimistic Outlook

"We enter 2025 with tremendous momentum and look forward to strong financial performance and several important Phase 3 readouts which, if positive, will further accelerate our long-term growth," stated CEO David Ricks, highlighting the company's optimistic outlook for the future.

Following the earnings release, Eli Lilly's stock saw a 2.12% increase in premarket trading, reflecting investor confidence in the company's growth trajectory.